News and Events
Stay informed about RECOVER’s Long COVID research by reading the latest news and participating in upcoming events.
Featured News Item
A year of discovery: Looking back at 2025 and ahead to 2026
In 2025, RECOVER’s progress included closing the first phase of its adult observational study and publishing its first clinical trial results. This year, the initiative continues its studies and sharing research findings.
Feature
54 Results
54 Results
R3 Seminar Recap: Ethical considerations for enrolling “invested parties” in large-scale clinical studies: Insights from the RECOVER Initiative
During the January 28th RECOVER Research Review (R3) Seminar, Dr. Kellie Owens, PhD (NYU Grossman School of Medicine) shared ethical guidance for enrolling individuals in clinical studies who have direct involvement with the research. Dr. Owens was joined by co-authors Leah Castro, MA (RECOVER Community and Caregiver Representative) and Rebecca Letts (RECOVER Patient and Caregiver Representative), who described Representatives’ important role in designing RECOVER clinical studies and developing peer-reviewed research publications.
R3 Seminar Recap
RECOVER study finds COVID-19 increases risk of developing ME/CFS
RECOVER researchers found that people were more likely to develop myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after having COVID-19. Most of the people who developed ME/CFS also developed Long COVID.
Feature
A person’s sex may affect their risk of developing Long COVID
Some women taking part in RECOVER research were more likely to experience Long COVID compared to men.
Announcement
NIH-funded study finds cases of ME/CFS increase following COVID-19
Results from a recent RECOVER study suggest that adults who have COVID-19 may be more likely to develop a related condition called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
News Release
New insights on Long COVID symptoms in adults highlight update to RECOVER study findings
Data provided by more than 3,800 new study participants reinforce how the long-term effects of COVID-19 can be different for everyone.
Announcement
Reviewing RECOVER’s impact in 2024
In 2024, RECOVER continued to advance scientific understanding of Long COVID through observational studies, clinical trials, and community engagement.
Feature
NIH directors highlight RECOVER’s progress and impact
Editorial by NIH leaders shares how RECOVER has worked and will continue working to ease the suffering of those living with Long COVID.
Announcement
NIH adds funds to Long COVID research, advances work on new clinical trials
The $662 million in funds received in 2024 will ensure that researchers can continue making progress toward understanding, diagnosing, preventing, and treating Long COVID through 2029.
News Release